CSIMarket
 


Regenerx Biopharmaceuticals inc   (RGRX)
Other Ticker:  
 

Cumulative Regenerx Biopharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

RGRX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

RGRX Working Capital Ratio for Trailing Twelve Months Period

(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Current Liabilities Growth 346.55 % 28.8 % 14.06 % -31.61 % -6.65 %
Y / Y Current Assets Growth -86.87 % -75.48 % -67.76 % -64.71 % 274.15 %
Working Capital Ratio for Trailing Twelve Months Period 0.51 1.32 1.96 2.65 3.08
Total Ranking # 3894 # 3318 # 2371 # 2092 # 1940
Seq. Current Liabilities Growth 225.01 % 16.27 % 10 % 7.42 % -6.26 %
Seq. Current Assets Growth -59.84 % -38.54 % -31.17 % -22.69 % -25.01 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2023
On the trailing twelve months basis Due to doubling in Current Liabilities in the I. Quarter to $2 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 0.51 below Regenerx Biopharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 536 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Regenerx Biopharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about RGRX
Working Capital Ratio RGRX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 537
Sector # 1103
S&P 500 # 4272


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
3.76 1.7 0.29
(Dec 31 2019)   (Dec 31 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Pfizer Inc  1.39 
Sonnet Biotherapeutics Holdings Inc   1.38 
Nanobiotix S a   1.38 
Ibio inc   1.37 
Bristol myers Squibb Company  1.35 
Clovis Oncology inc   1.35 
Theratechnologies Inc   1.34 
Abvc Biopharma Inc   1.33 
Athenex Inc   1.33 
Akebia Therapeutics Inc   1.30 
Dmk Pharmaceuticals Corporation  1.29 
Aquestive Therapeutics Inc   1.27 
Promis Neurosciences inc   1.26 
Novartis Ag  1.26 
Intelgenx Technologies Corp   1.25 
Mallinckrodt Plc  1.23 
Avenue Therapeutics Inc   1.19 
Journey Medical Corporation  1.18 
Apexigen Inc   1.17 
Assertio Holdings inc   1.15 
Genelux Corporation  1.14 
Avalo Therapeutics Inc   1.14 
Bausch Health Companies Inc   1.12 
Celularity Inc   1.12 
Optinose Inc   1.11 
Scisparc Ltd   1.09 
Teva Pharmaceutical Industries Limited  1.08 
Novan Inc   1.08 
Lannett Company Inc  1.07 
Neptune Wellness Solutions Inc   1.07 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com